Company profile
Stoke Therapeutics, Inc.
NASDAQ: STOK · Healthcare · Biotechnology
PublicHQ Bedford, MACIK 0001623526Reports USD
#297 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
60CFH 72DQ 37GM 69SS 64
v0.1 · 65/100 weight · provisional
↑ Altman-Z, 3-yr revenue growth · ↓ growth stability, Piotroski F
Methodology →Revenue TTM
$32.1M
Rev growth YoY (TTM)
-83.2%
Net income (FY)
-$6.9M
Employees
170
as of 2026-08-09
Market cap
$2.1B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$184.4M$184.4M2025
Net income-$6.9M-$6.9M2025
Operating income-$20.6M-$20.6M2025
Total assets$418.4M$418.4M2025
Liabilities$66.0M$66.0M2025
Equity$352.5M$352.5M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License71%
Service29%
By geography
Not disclosed.
The read
What is Stoke Therapeutics, Inc.’s revenue?
Stoke Therapeutics, Inc. booked $184.4M in FY2025 revenue, growing 405% year over year — faster than 93% of Healthcare companies we track, at a -3.7% net margin.
Peers · Healthcare
biote Corp.63CRhythm Pharmaceuticals, Inc.60CMaravai LifeSciences Holdings, Inc.53DHeartflow, Inc. Common Stock44DPhathom Pharmaceuticals, Inc.47DMedicine Man Technologies, Inc.——Key facts
CEOIan F. Smith
SectorHealthcare
IndustryBiotechnology
HeadquartersBedford, MA
ExchangeNASDAQ: STOK
Employees170
IPO date2019-06-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.